Human IgG1 / k monoclonal antibody with capacity for binding to interleukin 17A (IL-17A) by blocking and inhibiting the release of proinflammatory cytokines. It is used on the treatment of Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis. It is being studied as a treatment of Rheumatoid Arthritis and Uveitis. At latest update relevant published data on excretion into breast milk were not found. Any excretion into breastmilk in a significant amount seems very unlikely because it does not reach a high plasma levels (EMA 2016: 27 to 55 mg / L), has a very high molecular weight and a high binding capacity to plasma proteins. Its low oral bioavailability suggests that the passage to infants' plasma through the ingested breast milk would be nil or low, except in preterm infants and immediate neonatal period, for which there may be a greater intestinal absorption. It is well tolerated without serious side effects which most frequently are mild upper respiratory symptoms and mild diarrhea.